Scott Rocklage and 5AM Lead Financial Support for Muscular Dystrophy Research

According to recent press releases, Expansion Therapeutics has been gathering Series A financing in order to increase its number of drugs that target genetic disorders such as myotonic dystrophy type 1 (DM1), which is the primary cause of adult onset muscular dystrophy. This financing effort was headed by 5AM Ventures, Novartis Venture Fund and Kleiner Perskins, with participation from Alexandria Venture Investments and RA Capital Management. Scott Rocklage, Ph.D., the Managing Partner of 5AM Ventures and also the Chairman of the Board of Directors for Expansion Therapeutics, stated that Expansion Therapeutics had formulated a plan to use the capital efficiently in order to advance the number of drugs that target RNA molecules in diseases like DM1.

 

Certain RNAs, which are molecules from DNA that have been changed to proteins, reach toxic levels in people with this genetic tendency and cause the resulting nervous system deterioration associated with DM1. Currently, there is no effective treatment for DM1. Expansion Therapeutics has based its scientific methods on research from The Scripps Research Institute’s Matthew D. Disney, Ph.D., who, according to Scott Rocklage, is the leader of the scientific team that is conducting the research.

 

Scott Rocklage is the founder and Managing Partner over 5AM Ventures. Scott Rocklage received a B.S. degree in Chemistry from the University of California, Berkeley and a Ph.D. degree in Chemistry from the Massachusetts institute of Technology (MIT). During his time at MIT, Scott Rocklage performed research in the laboratory of Richard Schrock, who received the Nobel Peace Price in Chemistry in 2005.

 

With more than 30 years of healthcare management experience, Scott Rocklage has had success having medications like Teslascan, Cubicin and Omniscan receive FDA approval. Scott Rocklage has more than 30 United States patents for personal and co-authored inventions, and a large number of his published works have been peer-reviewed. Scott Rockladge also has held many leadership roles such as the chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and is currently the Chairman of the Board for Kinestral, Cidara and Rennovia.

 

Scott Rocklage and 5AM Ventures are looking forward to continuing to support these efforts to develop drugs to combat genetic diseases for patients who have few treatment options. All the participants in this joint approach are optimistic about future results, and Scott Rocklage will continue to leverage his financial and medical experience to advance this work.

 

Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.

Category: People

Leave a Reply

Your email address will not be published. Required fields are marked *